Takeshi Machida

Dr. Takeshi Machida

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
MHManabu Hayashi
Manabu Hayashi
TMTakeshi Machida
Takeshi Machida
YIYumi Ishida
Yumi Ishida
YOYusuke Ogata
Yusuke Ogata
TOTomoko Omori
Tomoko Omori
HSHideharu Sekine
Hideharu Sekine
The complement system, a part of the innate immune system, can be activated via three different pathways. In the alternative pathway, a factor D (FD) plays essential roles in both the initiation and the amplification loop and circulates as an active form. Mannose-binding lectin–associated serine proteases (MASPs) are key enzymes of the lectin pathway, and MASP-1 and/or MASP-3 are reported to be involved in the activation of FD. In the current study, we generated mice monospecifically deficient for MASP-1 or MASP-3 and found that the sera of the MASP-1–deficient mice lacked lectin pathway activity, but those of the MASP-3–deficient mice lacked alternative pathway activity with a zymogen FD. Furthermore, the results indicate that MASP-3 but not MASP-1 activates the zymogen FD under physiological conditions and MASP-3 circulates predominantly as an active form. Therefore, our study illustrates that, in mice, MASP-3 orchestrates the overall complement reaction through the activation of FD.

31 October 2022 in Immunological Reviews
Verified
Journal Article
Closed access
HSHideharu Sekine
Hideharu Sekine
TMTakeshi Machida
Takeshi Machida
TFTeizo Fujita
Teizo Fujita

30 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JHJunya Hata
Junya Hata
TMTakeshi Machida
Takeshi Machida
KMKanako Matsuoka
Kanako Matsuoka
SHSeiji Hoshi
Seiji Hoshi
HAHidenori Akaihata
Hidenori Akaihata
YKYoshiyuki Kojima
Yoshiyuki Kojima
The pathophysiology of benign prostatic hyperplasia (BPH) remained unclear. Here, we concentrated on the complement activation in the growth of BPH using a rat model. BPH tissues were harvested from rats after rat urogenital sinus implantation. The local expression and deposition levels of C1q, C3, mannose-binding lectin (MBL), factor B (FB), and C5b-9 in the rat and human BPH tissues were analyzed by real-time RT-PCR, western blotting and immunohistochemistry (IHC). Serum IgG levels in the rat BPH model were analyzed by ELISA, and IHC was used to assess tissue localization. Proteins binding serum IgG autoantibody in the BPH rats were isolated by immunoprecipitation. C1q, C3, MBL, FB and C5b-9 were highly localized in rat BPH tissues compared to normal tissues. In contrast, C3, FB and C5b-9, but not C1q and MBL, were abundantly detected in human BPH tissues compared to normal tissues. Diffuse localization of IgG in rat BPH tissues was found. Heat shock protein 90, annexin, α-smooth muscle actin, and β-actin were identified as targets for IgG autoantibodies in the BPH model. Our results strongly suggested the role for complement activation in the growth process of BPH, likely triggered by classical pathway activation with autoantibodies.

30 April 2022 in Ophthalmology Science
Verified
Journal Article
Open access
YKYutaka Kato
Yutaka Kato
YOYasuharu Oguchi
Yasuharu Oguchi
TOTomoko Omori
Tomoko Omori
AKAkihito Kasai
Akihito Kasai
MOMasashi Ogasawara
Masashi Ogasawara
TSTetsuju Sekiryu
Tetsuju Sekiryu
To investigate the association of risk alleles in complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) with complement activation products in the aqueous humor in eyes with neovascular age-related macular degeneration (nAMD) including polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), and pachychoroid neovasculopathy (PNV). Prospective, comparative, observational study. Treatment-naïve patients with nAMD and cataract patients as controls. The study included 236 eyes of 236 patients with nAMD and 49 control eyes of 49 patients. Aqueous humor samples were collected from 67 eyes with drusen-associated nAMD, 72 eyes with PCV, 26 eyes with RAP, and 71 eyes with PNV before intravitreal anti-VEGF injection and cataract surgery in the 49 control eyes. Clinical samples were measured for complement component 3a (C3a), C4a, and C5a using a bead-based immunoassay. Genotyping of the ARMS2 A69S (rs10490924), CFH I62V (rs800292), and CFH Y402H (rs1061170) was performed using TaqMan genotyping. The levels of complement activation products (C3a, C4a, and C5a) in the aqueous humor in each genotype of ARMS2 and CFH. The C3a level in the aqueous humor was significantly elevated (P = 0.006) in patients with nAMD and the ARMS2 A69S risk allele, whereas the levels of the complement activation products were not associated with CFH I62V and Y402H genotypes. Among the control eyes, no significant differences were seen in any complement activation products for all genetic polymorphisms. The levels of the complement activation products in the aqueous humor of eyes with the nAMD subtypes for each genetic polymorphism did not show significant differences. The C3a concentration in the aqueous humor was significantly higher in Japanese nAMD patients with the ARMS2 A69S risk allele, whereas it was not elevated in the patients with CFH I62V. Age-related maculopathy susceptibility 2 A69S polymorphism is strongly associated with local complement activation in nAMD patients.

16 August 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
KKKohei Kusakari
Kohei Kusakari
TMTakeshi Machida
Takeshi Machida
YIYumi Ishida
Yumi Ishida
TOTomoko Omori
Tomoko Omori
TSToshiyuki Suzuki
Toshiyuki Suzuki
HSHideharu Sekine
Hideharu Sekine
The complement system plays an important role in host defense and is activated via three different activation pathways. We have previously reported that mannose-binding lectin-associated serine protease (MASP)-3, unlike its splicing variant MASP-1, circulates in an active form and is essential for the activation of the alternative pathway (AP) via the activation of complement factor D (FD). On the other hand, like MASP-1 and MASP-2 of the lectin pathway (LP), MASP-3 forms a complex with the pattern recognition molecules (PRMs) of the LP (LP-PRMs). Both MASP-1 and MASP-2 can be activated efficiently when the LP-PRMs complexed with them bind to their ligands. On the other hand, it remains unclear how MASP-3 is activated, or whether complex formation of MASP-3 with LP-PRMs is involved in activation of MASP-3 or its efficiency in the circulation. To address these issues, we generated wild-type (WT) and four mutant recombinant mouse MASP-3 proteins fused with PA (human podoplanin dodecapeptide)-tag (rmMASP-3-PAs), the latter of which have single amino acid substitution for alanine in the CUB1 or CUB2 domain responsible for binding to LP-PRMs. The mutant rmMASP-3-PAs showed significantly reduced in-vivo complex formation with LP-PRMs when compared with WT rmMASP-3-PA. In the in-vivo kinetic analysis of MASP-3 activation, both WT and mutant rmMASP-3-PAs were cleaved into the active forms as early as 30 minutes in the circulation of mice, and no significant difference in the efficiency of MASP-3 cleavage was observed throughout an observation period of 48 hours after intravenous administration. All sera collected 3 hours after administration of each rmMASP-3-PA showed full restoration of the active FD and AP activity in MASP-3-deficient mouse sera at the same levels as WT mouse sera. Unexpectedly, all mutant rmMASP-3-PAs showed faster clearance from the circulation than the WT rmMASP-3-PA. To our knowledge, the current study is the first to show in-vivo kinetics of MASP-3 demonstrating rapid activation and clearance in the circulation. In conclusion, our results demonstrated that the complex formation of MASP-3 with LP-PRMs is not required for in-vivo activation of MASP-3 or its efficiency, but may contribute to the long-term retention of MASP-3 in the circulation.

26 March 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MTMika Takasumi
Mika Takasumi
TOTomoko Omori
Tomoko Omori
TMTakeshi Machida
Takeshi Machida
YIYumi Ishida
Yumi Ishida
MHManabu Hayashi
Manabu Hayashi
HSHideharu Sekine
Hideharu Sekine
Inhibition of the complement activation has emerged as an option for treatment of a range of diseases. Activation of the lectin and alternative pathways (LP and AP, respectively) contribute to the deterioration of conditions in certain diseases such as ischemia‐reperfusion injuries and age‐related macular degeneration (AMD). In the current study, we generated dual complement inhibitors of the pathways MAp44‐FH and sMAP‐FH by fusing full‐length MAp44 or small mannose‐binding lectin‐associated protein (sMAP), LP regulators, with the N‐terminal five short consensus repeat (SCR) domains of complement factor H (SCR1/5‐FH), an AP regulator. The murine forms of both fusion proteins formed a complex with endogenous mannose‐binding lectin (MBL) or ficolin A in the circulation when administered in mice intraperitoneally. Multiple complement activation assays revealed that sMAP‐FH had significantly higher inhibitory effects on activation of the LP and AP in vivo as well as in vitro compared to MAp44‐FH. Human form of sMAP‐FH also showed dual inhibitory effects on LP and AP activation in human sera. Our results indicate that the novel fusion protein sMAP‐FH inhibits both the LP and AP activation in mice and in human sera, and could be an effective therapeutic agent for diseases in which both the LP and AP activation are significantly involved.